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Summary
Background Although the role of immunoglobulin E (IgE) in immunity against helminth
parasites is unclear, there is concern that therapeutic antibodies that neutralize IgE (anti-IgE)
may be unsafe in subjects at risk of helminth infection.
Objective We conducted an exploratory study to investigate the safety of omalizumab (anti-
IgE) in subjects with allergic asthma and/or perennial allergic rhinitis at high risk of intestinal
helminth infection. The primary safety outcome was risk of infections with intestinal
helminths during anti-IgE therapy.
Methods A randomized, double-blind, placebo-controlled trial was conducted in 137 subjects
(12–30 years) at high risk of geohelminth infection. All subjects received pre-study
anthelmintic treatment, followed by 52 weeks’ treatment with omalizumab or placebo.
Results Of the omalizumab subjects 50% (34/68) experienced at least one intestinal
geohelminth infection compared with 41% (28/69) of placebo subjects [odds ratio (OR) 1.47,
95% conﬁdence interval (CI) 0.74–2.95, one-sided P=0.14; OR (adjusted for study visit,
baseline infection status, gender and age) 2.2 (0.94–5.15); one-sided P=0.035], providing
some evidence for a potential increased incidence of geohelminth infection in subjects
receiving omalizumab. Omalizumab therapy was well tolerated, and did not appear to be
associated with increased morbidity attributable to intestinal helminths as assessed by clinical
and laboratory adverse events, maximal helminth infection intensities and additional
anthelmintic requirements. Time to ﬁrst infection (OR 1.30, 95% CI 0.79–2.15, one-sided
P=0.15) was similar between treatment groups. Infection severity and response to
anthelmintics appeared to be unaffected by omalizumab therapy.
Conclusions In this exploratory study of allergic subjects at high risk of helminth infections,
omalizumab therapy appeared to be safe and well tolerated, but may be associated with a
modest increase in the incidence of geohelminth infection.
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Introduction
Intestinal helminth infections caused by Ascaris lumbri-
coides, hookworm, Trichuris trichiura and Strongyloides
stercoralis are the most prevalent helminth parasitic
infections in humans, infecting approximately 2 billion
people worldwide [1]. The vast majority of helminth
infections do not lead to associated clinical morbidity
even in those areas where such infections are a public
health concern [2]. Helminth antigens are potent inducers
of immunoglobulin E (IgE) production and are capable of
stimulating an IgE response in almost all infected
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tially with persistent exposure to helminth parasites, the
role of IgE in mediating a protective anti-helminth im-
mune response remains controversial [4]. Animal studies
indicatethatimmuneresponsestohelminthsinvolvemulti-
ple effector pathways directed against different stages of
the helminth life cycle [5]. Current evidence in humans
indicates that protective immunity against intestinal hel-
minths is mediated by type-2 cytokine immune responses
[6]. There is little consistent evidence to suggest that
antibodies of any particular isotype or subclass represent
a primary effector mechanism against these parasites [4].
Omalizumab (Xolair
s, Novartis Pharmaceuticals Cor-
poration) is a novel humanized anti-IgE monoclonal anti-
body licensed for the treatment of allergic asthma (AA). In
clinical studies, omalizumab has been shown to provide
effective control of AA and perennial allergic rhinitis
(PAR) [7–14]. Omalizumab binds IgE and inhibits binding
to high-afﬁnity (Fc˚ aRI) IgE receptors on mast cells and
basophils, thereby reducing mediator release at the start of
allergic responses [15].
There is concern that neutralizing IgE may adversely
affect immunity to helminth parasites. To further char-
acterize the safety proﬁle of omalizumab, we need to
determine whether treatment is safe in patients exposed
to intestinal helminth infection and whether susceptibility
to infection isincreased,particularly in patientswhotravel
to or live in areas in which these infections are endemic.
We conductedanexploratorystudyusing arandomized,
placebo-controlled design to investigate three speciﬁc
issues relating to the safety of omalizumab treatment in
allergic individuals at risk of intestinal helminth infec-
tions: (1) the incidence of intestinal helminth infection; (2)
clinical and laboratory adverse events (AEs) that could be
associated with disease caused by intestinal helminths and
other safety parameters associated with infection; and (3)
the effect of treatment on time to infection.
Methods
Subjects
Males and females aged 12–30 years with a diagnosis of
AA for X1 year and/or a clinical history of PAR for 42
years, a body weight of 20–150kg, platelet levels of at
least 130 10
9/L and either a current geohelminth infec-
tion (any of A. lumbricoides, T. trichiura, hookworm,
S. stercoralis or Enterobius vermicularis) or a high risk of
infection were enrolled. ‘High risk of infection’ was
deﬁned as having had at least one of the following:
documented history of geohelminth infection or living
with a household member with a current or documented
history of geohelminth infection within the previous year,
or a positive RAST for Ascaris-speciﬁc IgE at screening
and a self-reported geohelminth infection within the
previous year. Self-reporting of infection was always
validated by medical records or RAST. The exclusion
criteria were as follows: total IgE X1300IU/mL; weight
420kg or 4150kg; weight-to-IgE ratios that fell out-
side values that permitted dosing as set out in the dosing
table; a history of severe anaphylactoid or anaphylactic
reaction(s); use of oral corticosteroids or high dose of
inhaled corticosteroids (4500mg ﬂuticasone or 4800m
g budesonide per day) within 4 weeks of the study or
likelihood of needing regular-inhaled corticosteroids at
such doses during the study; and use of methotrexate,
gold salts, cyclosporine or troleandomycin within
3 months of the study.
Ethical approval was obtained from the institutional
review boards of each study centre and by the Brazilian
National Commission for Ethics in Research (CONEP). All
subjects (or their parents or guardians) gave written
informed consent. The study was conducted in accordance
with the principles of the Declaration of Helsinki and
European Community and US Food and Drug Administra-
tionregulations. A DataSafetyMonitoringBoardanalysed
data during the course of the study to advise the clinical
study team of any potential modiﬁcations to the study
conduct necessary to minimize potential risks to subjects.
Study design
This was a randomized, double-blind, parallel-group,
placebo-controlled study conducted at seven urban cen-
tres in Brazil (Salvador, Curitiba, Rio de Janeiro, Goiania,
Recife and two centres in Fortaleza). The study comprised
a 4-week screening period, when subjects received an-
thelmintic treatment to clear intestinal and other helminth
infections as well as routine care to treat asthma and PAR.
This treatment could include the use of long-acting b2-
agonists, inhaled or nasal steroids, leucotriene inhibitors/
receptor antagonists or antihistamines. Subjects were not
included if they required 4500mg ﬂuticasone or 4800
mg budesonide/beclometasone per day on a regular basis
to avoid potential confounding effects of the potential
albeit unlikely broad immunosuppressive actions of these
medicines that could lead to an increased susceptibility to
geohelminth infection. Subjects receiving allergen-speci-
ﬁc subcutaneous immunotherapy were also eligible, but
such a treatment could not be initiated during the study.
The screening period was followed by a 52-week treat-
ment period, during which subjects received subcuta-
neous omalizumab or placebo, followed by albendazole
treatment at the end of the 52 weeks and a 12-week
follow-up period.
Randomization
Subjects were assigned to treatment groups using a
randomization number provided by Novartis Drug Supply
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(Almedica Drug Labeling System, Version 5.3 a, Almedica
Technology Group Inc., Allendale, NJ, USA). Blocks of
four randomization numbers were allocated to each treat-
ment centre. Investigators and personnel in the Quality
Assurance Biostatistics Group in the Novartis Biostatistics
and Statistical Reporting Group held randomization
details and were authorized to unmask individual sub-
ject assignments only in case of emergency. Treat-
ment allocation was unblinded after the study had been
completed and all data had been computer entered and
locked.
Intervention
Omalizumab dosage and dosing frequency was cal-
culated based on body weight and total serum IgE
levels measured at screening. Subjects received either
omalizumab 150 or 300mg every 4 weeks or 225, 300 or
375mg every 2 weeks. The amount of omalizumab
to administer, and whether to dose every 2 or every
4 weeks, is based on patient body weight and IgE level
set out in a dosing table (Appendix A1). Open-label
omalizumab or placebo supplies were shipped to each
site and reconstituted by a speciﬁed individual who
was instructed not to reveal the identity of the drug to
the subjects, investigator or Novartis personnel involved
in conducting, monitoring or analysing the data in this
trial.
Anthelmintic treatment
All subjects were treated with broad-spectrum anthelmin-
tic drugs before the start of the study: a single dose of
400mg of albendazole, followed by a repeat dose of
albendazole plus 150mg/kg of ivermectin 14 days later
(i.e. 7 days before the dose of study drug). Ivermectin
would be expected to have 495% cure rates for
S. stercoralis [15] and two doses of albendazole would
be expected to have 495% cure rate for other intestinal
helminth infections, except T. trichiura [15]. The combi-
nation of albendazole/ivermectin is more efﬁcacious than
either drug alone for infections with T. trichiura [16].
Subjects with schistosomiasis were treated with a
standard dose of praziquantel or oxamniquine. During
the treatment period, anti-parasite therapy was initiated
if the measured eggs per gram (epg) of faeces for a
particular parasite was above the following pre-deﬁned
safety thresholds: A. lumbricoides, 1000; hookworm, 200;
T. trichiura, 1000; and Schistosomiasis mansoni, 500.
Strongyloides infection was treated with one dose of
ivermectin and the subject was withdrawn from the study
at the next visit if the infection persisted. At the end of
week 52 of treatment, all subjects received anthelmintic
treatment.
Subject assessments and laboratory analyses
The following assessments were undertaken every 4 weeks
during the treatment and follow-up periods: faeces sam-
pling, spirometry, vital signs, physical examination, preg-
nancy testing and recording of AEs. Routine laboratory
assessments for haematology, clinical chemistry and
urinalysis were performed every 12 weeks.
Faeces samples were examined at a central laboratory
(Fleury, Brazil) using both a direct wet mount technique
[17] and the modiﬁed Kato–Katz method [17] for the
detection and quantiﬁcation of intestinal helminth infec-
tions and the Baermann method for detection of Strongy-
loides larvae [18]. A parasite infection identiﬁcation ﬂow
chart was used in the study and is shown in Fig. 1.
Infection intensity was quantiﬁed by egg counts and
reported as epg of faeces. Faeces samples were also
analysed using appropriate methods at local laboratories
to ensure a rapid turnaround of samples. Local sampling
facilities were used for determination of positive helminth
infections, but not for quantiﬁcation. For standardization
purposes, all egg count values reported are from the
central laboratory. In addition, serology was performed
before randomization in a subset of subjects at a single
centre (Salvador) to detect prior exposure to S. stercoralis,
using an ELISA to detect speciﬁc IgG [19], and reactions
were classiﬁed as positive, equivocal or negative.
Outcome variables
The primary safety outcome was the rate of intestinal
geohelminth parasite infection. The time to ﬁrst detection
of infection with intestinal geohelminth parasites was also
evaluated. The classiﬁcation of intestinal helminth infec-
tion status during the study is described in Fig. 1.
Other safety outcomes were clinical AEs, relevant
laboratory measurements (peripheral eosinophil counts,
liver function and haemoglobin), maximal helminth in-
fection intensities during the study and requirement for
additional anthelmintic treatments. Clinical AEs were
graded as mild, moderate or severe. Serious AEs were also
recorded and were deﬁned as events that were fatal or life-
threatening, required hospitalization, were signiﬁcantly
or permanently disabling or incapacitating, constituted a
congenital anomaly or a birth defect or were considered
medically signiﬁcant.
Statistical analysis
The study was exploratory and the planned sample size of
70 subjects per treatment arm was based primarily on
practical considerations. From this practical perspective,
identifying allergic subjects at high risk of geohelminth
infection who had IgE levels within the inclusion criteria
limits was always likely to prove challenging. The
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meaningful number of infection events to be evaluated in
an experimental context. Seventy patients per arm were
considered to provide important safety data in this group
of subjects, and would allow large effects on geohelminth
infection to be detected.
The geohelminth infection rates were analysed using
logistic regression, with treatment, dose schedule and
study centre as covariates. A secondary analysis was
performed to adjust for additional variables including
those for which imbalances were present at baseline
and adjusted for study visit, baseline infection status,
gender and age. Time to infection with intestinal geohel-
minths was estimated using Kaplan–Meier analyses to
evaluate infection-free status within each treatment group
and the relative risk (RR) calculated using a Cox’s regres-
sion model with dosing schedule and pooled centre as
covariates.
One-sided P-values in favour of placebo were presented
for omalizumab relative to placebo, with Po0.025 sug-
gesting excessive risk and P40.10 suggesting no exces-
sive risk. The study was not powered for formal hypothesis
testing of geohelminth reinfection risk, and one-sided
P-values were presented as a safety signal for an increase
in the incidence of infections with omalizumab relative to
placebo.
Results
Baseline characteristics and subject follow-up
This study was conducted between November 2001 and
March 2004. A total of 455 subjects were screened and
137 were randomized (omalizumab, n=68; placebo,
n=69; Fig. 2). Treatment and follow-up periods were
completed by 88% (121/137) of subjects (omalizumab,
59/68: placebo, 62/69). There were non-statistically sig-
niﬁcant but relevant baseline imbalances between the two
groups for the frequency of active infections in the
placebo group (40.6% vs. 27.9%) and a greater proportion
Fig. 1. Flow chart for determining intestinal helminth infection status. Intestinal helminth infections were deﬁned as new infections if helminth eggs
were detected in a faeces sample following a previously negative sample, or there was an increase in infection intensity [eggs per gram (epg)] for the
same species at least 4 weeks after appropriate anthelmintic treatment or an increase in infection intensity (epg) for the same parasite species compared
with the previous sample. The start date of a new infection was deﬁned as the date on which the positive sample was taken. The end of a helminth
infection was deﬁned as the date on which either (1) anthelmintic treatment was given to treat a speciﬁc helminth infection or (2) no eggs/larvae were
detected andthe investigator consideredthe infectionresolved or (3) whenanthelmintictreatment was administered at the end of the 52-weektreatment
period.
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group (48.5% vs. 36.2%; Table 1). Treatment groups were
balanced for the distribution of subjects between dosing
regimens of the study drug (data not shown). All subjects
were free of intestinal geohelminth infection at the start of
the 52-week treatment period.
Fig. 2. Flow of subjects through the study.
Table 1. Summary of baseline demographics and clinical characteristics
Omalizumab (n=68) Placebo (n=69)
Males, n (%) 33 (48.5) 25 (36.2)
Median age (years; range) 15 (12–29) 16 (12–30)
Median total serum IgE (IU/mL; range) 403 (39–1100) 397 (50–1231)
Median FEV1 (% predicted; range) 68 (33–105) 78 (40–103)
Allergy history
AA, n (%) 48 (70.6) 52 (75.4)
Median duration of AA, years (range) 11 (0–26) 12 (1–24)
PAR patients, n (%) 64 (94.1) 65 (94.2)
Median duration of PAR, years (range) 6 (0–26) 8 (1–21)
Infection status at screening
Active infection, n (%) 19 (27.9) 28 (40.6)
History of any intestinal helminth infection in previous year, n (%) 43 (63.2) 53 (76.8)
Positive RAST test for Ascaris-speciﬁc IgE, n (%) 7 (10.3) 7 (10.1)
Strongyloides stercoralis infection
w (n) 2 9 (13.0)
Household member with documented active/history of any intestinal
helminth infection in previous year, n (%)
18 (26.5)
Based on positive egg count in faeces sample collected at screening.
wSerology for S.stercoraliswasperformedina subsetof51 subjects.Equivocalresultswere obtainedinanother ﬁvesubjects (3/26with omalizumaband
2/25 with placebo).
IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; AA, allergic asthma; PAR, perennial allergic rhinitis.
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Over the treatment period, 50% (34/68) of omalizumab
subjects experienced at least one intestinal geohelminth
infection compared with 41% (28/69) of placebo subjects.
There appeared to be a greater risk of intestinal helminth
infection in the omalizumab group during the 52-week
treatment period [odds ratio (OR) 1.47, 95% conﬁdence
interval (CI) 0.74–2.95, one-sided P=0.14], although the
95% CI is consistent with no effect (i.e. OR of 1). When
adjusted for study visit, baseline infection status, gender
and age, the OR was 2.2 (95% CI 0.94–5.15; one-sided
P=0.035).
Time to ﬁrst intestinal helminth infection after anthel-
mintic treatment provided during the initial screening
phase of the study was similar in omalizumab and placebo
groups [RR for treatment effect, 1.3 (95% CI 0.79–2.15;
one-sided P=0.150)]. The number of geohelminth infec-
tions by time and the Kaplan–Meier plot for time to ﬁrst
detection of infection are shown in Fig. 3, and indicate a
possible trend for increased infection risk in the omalizu-
mab group after 28 weeks of treatment.
The total number of subjects experiencing each type
of geohelminth infection is presented in Table 2.
Multiple new infections with A. lumbricoides were ob-
served in two of 68 (2.9%) individuals in the omalizumab
group but no multiple infections were observed in the
placebo group.
The clinical severity of parasite infections was similar
between treatment groups. None of the parasite infections
experienced by subjects in either treatment group was
considered to be clinically severe by the investigators at
the study centres.
Clinical adverse events
AEs could be attributed to the study drug or intestinal
helminth infections. The distribution of AEs was similar
between treatment groups, with the exception of a higher
incidence of skin and subcutaneous tissue disorders in the
omalizumab group compared with the placebo group
(Table 3). The incidence of urticaria (which could poten-
tially be attributed to intestinal helminth infections) was
very low in both treatment groups (one subject in each
group). Severe AEs were reported in ﬁve omalizumab-
treated subjects and four placebo recipients (Table 3).
Three serious AEs, i.e. events that were fatal or life-
threatening, required hospitalization, were signiﬁcantly
or permanently disabling or incapacitating, constituted a
congenital anomaly or a birth defect or were considered
medically signiﬁcant, were reported (one omalizumab and
Fig. 3. Kaplan–Meier plot of time to ﬁrst detection of infection with intestinal helminth parasite during core and follow-up phases. These data include
data for discontinued patients, so the number of patients infected in this analysis (36 vs. 29) differs slightly from the number of reported infections
during the 52-week treatment period (34 vs. 28).
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considered to be treatment related. Three subjects left the
study due to AEs in each treatment group (placebo:
pregnancy; tuberculosis; omalizumab: pregnancy). None
of the events were considered treatment related.
Laboratory evaluations
Laboratory analyses revealed few haematological or bio-
chemical changes, with no clinically or statistically rele-
vant differences between treatment groups. Of particular
interest were AEs that could be associated with geohel-
minth infections: low haemoglobin (intestinal blood loss
caused by adult worms); eosinophilia (parasite infection);
and elevation of alkaline phosphatase (ALP) and the liver
transaminases alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST; migration of helminth larvae
in the liver/liver function). The median baseline values
and mean change from baseline at 52 weeks for these
parameters were similar in the omalizumab and placebo
group (Table 4). One omalizumab-treated subject [1/68
(1.5%)] and one placebo recipient [1/69 (1.4%)] had
abnormally low haemoglobin levels (male: o11.5g/dL;
female o9.5g/dL) during the study. A trend towards
more frequent abnormally elevated levels of ALPand liver
transaminases was observed in omalizumab-treated sub-
jects vs. placebo recipients; ALT: omalizumab 11.8% (8/
68) vs. placebo 7.2% (5/69); AST: omalizumab 10.3% (7/
68) vs. placebo 7.2% (5/69) and ALP: omalizumab 20.6%
(14/68) vs. placebo, 8.7% (6/69). Ten of the 14 subjects
with elevated ALP in the omalizumab group had an
intestinal helminth infection during the study compared
with three of the six placebo recipients. However, two of
the 14 omalizumab and none of the six placebo-treated
subjects had elevated ALP levels at baseline. ALT and AST
levels were similar irrespective of geohelminth infection
in the two groups.
Clinical intervention for intestinal helminth infections
During the study, anthelmintic treatments were provided
if infection intensities increased above pre-deﬁned
thresholds. Similar numbers of subjects in the omalizu-
mab- and placebo-treated groups experienced geohel-
minth infections exceeding the thresholds during core
treatment plus follow-up periods (15 infections in nine
subjects in the omalizumab group compared with 12
infections in 11 subjects in the placebo group). One subject
in the omalizumab group experienced ﬁve infections that
exceeded the epg of faeces threshold caused by round-
worm (three infections), hookworm (one infection) and
whipworm (one infection). Two additional subjects in the
omalizumab-treated group received anthelmintic treat-
ments in error with lower egg counts than required by the
study protocol.
All appropriate anthelmintic treatments administered
for infections with A. lumbricoides, hookworm and
S. stercoralis infections during the study resulted in a cure
in both intervention groups. One subject in the omalizu-
mab group was treated with a single 400mg dose of
albendazole for whipworm infection, which reduced the
egg count below threshold but did not eliminate infection.
However, albendazole has a relatively low cure rate for the
treatment of whipworm [20].
Peak infection intensities
There was a wide variation in the intensity of intestinal
helminth infection. The median peak infection intensities
were similar between omalizumab and placebo-treated
Table 2. Number of subjects with intestinal geohelminth infection by helminth type during the 52-week treatment period
Omalizumab (n=68) Placebo (n=69)
Total number of subjects
with infection, n (%)
Total number
of infections
Total number of subjects
with infection, n (%)
Total number
of infections
Geohelminth infection 34 (50.0) 60 28 (40.6) 42
Ascaris lumbricoides 21 (30.9) 28 16 (23.2) 16
Hookworm
w 5 (7.4) 5 8 (11.6) 8
Trichuris trichiura 15 (22.1) 15 9 (13.0) 10
Enterobius vermicularis 11 (16.2) 12 6 (8.7) 6
Strongyloides 0 0 2 (2.9) 2
Other helminth infections 4 (5.9) 4 3 (4.3) 3
Hymenolepis nana 0 0 2 (2.9) 2
Schistosoma mansoni 4 (5.9) 4 1 (1.4) 1
Enteric protozoa infections 34 (50.0) 47 31 (44.9) 43
P=0.06 for overall comparison of geohelminth infection rate (repeated measures logistic regression with treatment, dosing schedule, centre and study
visit as factors).
wAncylostoma and Necator spp. Protozoa identiﬁed were Blastocystis hominis, Chilomastix mesnili, Endolimax nana, Entamoeba coli, Entamoeba
histolytica, Giardia intestinalis and Iodamoeba butsc.
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432epg (range 24–29, 160) vs. placebo 1248epg (range
24–11328)]; T. trichiura [omalizumab, median 108epg
(range 48–1272) vs. placebo 60 (range 24–624)].
Discussion
We performed a randomized-controlled trial to evaluate
the safety of omalizumab in allergic subjects considered to
be at a high riskof infection with intestinal helminths. Our
ﬁndings provide evidence that omalizumab can be safely
administered to such patients but do not exclude a
possible increased risk of helminth infection in patients
at a high risk of infection. Because of the wide CIs for this,
our ﬁndings are consistent with a possible slightly in-
creased risk of infection, although this failed to reach
statistical signiﬁcance.
We do not believe that a possible increased risk of
infection with common intestinal helminth parasites is
likely to be of clinical signiﬁcance because no excess
clinical or relevant laboratory AEs were reported in the
omalizumab-treated group compared with placebo, with
the exception of: (1) a higher incidence of skin and
subcutaneous tissue disorders in the omalizumab group that
was related largely to injection site reactions and (2) a trend
towards more frequent abnormally elevated liver enzymes
that did not appear to be associated with intestinal helminth
infection. Peak infection intensities and requirement for
additional anthelmintic treatments during the course of the
study were comparable between treatment groups.
The main limitation of this exploratory study was the
relatively small sample size and therefore the low power
to detect a small increase, for the primary safety outcome,
in the risk of geohelminth infection. Based on the sample
size (approximately 70 subjects per treatment arm) and the
observed variance in the study, retrospective calculations
indicated that this exploratory study had an 80% power
to detect a 28% increase in the incidence of at least one
intestinal geohelminth infection in the omalizumab
group, over the 41% encountered in the placebo group
(0.05 signiﬁcance level, two-sided). Assuming a similar
treatment difference, it is possible to speculate that a
statistically signiﬁcant effect on risk of geohelminth
infection may have been observed in a larger study.
However, it is important to note that this is a high-risk
population and that there was only one (0.03%) reported
helminthic infection (pinworm) from 1934 patient-years
Table 3. Number (%) of subjects with adverse events during the 52-week
treatment period
Adverse events
Omalizumab
(n=68) n (%)
Placebo
(n=69) n (%)
Any adverse events 68 (100) 69 (100)
Suspected by investigator to be drug related 16 (23.5) 22 (31.9)
Severity
Mild 28 (41.2) 25 (36.2)
Moderate 35 (51.5) 40 (58.0)
Severe 5 (7.4) 4 (5.8)
Serious adverse events
w 1 (1.5) 2 (2.9)
System organ class affected (X5% in either treatment group)
Infections and infestations 66 (97.1) 68 (98.6)
Respiratory, thoracic and mediastinal
disorders
48 (70.6) 60 (87.0)
Nervous system disorders 38 (55.9) 50 (72.5)
Gastrointestinal disorders 35 (51.5) 39 (56.5)
Skin and subcutaneous tissue disorders 30 (44.1) 15 (21.7)
General disorders and administration
site conditions
21 (30.9) 22 (31.9)
Reproductive system and breast disorders 17 (25.0) 17 (24.6)
Musculoskeletal and connective tissue
disorders
14 (20.6) 20 (29.0)
Injury, poisoning and procedural
complications
14 (20.6) 11 (15.9)
Eye disorders 10 (14.7) 17 (24.6)
Ear and labyrinth disorders 5 (7.4) 3 (4.3)
Blood and lymphatic system disorders 3 (4.4) 4 (5.8)
Metabolism and nutrition disorders 3 (4.4) 4 (5.8)
Vascular disorders 1 (1.5) 4 (5.8)
Three omalizumab-treated subjects had a single severe adverse event
(AE; electiveabortion,headache, rhinitis)and2subjectshad2severe AEs
(chest pain/headache and anxiety/headache). One placebo recipient had
3 severe AEs (pregnancy, spontaneousabortion,giardiasis)and3 subjects
had a single severe AE (abdominal pain, hypotension, asthma).
wElective abortion (omalizumab-treated patient), spontaneous abortion
(placebo) and severe asthma exacerbation (placebo).
Table 4. Summary of changes in laboratory-evaluated biochemical parameters during the 52-week treatment period
Omalizumab (n=68) Placebo (n=69)
Mean change from
baseline at 52 weeks
Median at
baseline (range)
Mean change from
baseline at 52 weeks
Median at
baseline (range)
Parameter (units)
Haemoglobin (g/dL)  0.1 13.5 (11.3–16.0)  0.1 13.5 (9.8–17.8)
Eosinophils (%)  1.6 5.6 (1.4–26.5)  0.4 5.6 (0.9–21.9)
Alanine aminotransferase, ALT (U/L)  0.3 15.0 (9–44)  0.9 14.0 (7–78)
Alkaline phosphatase (serum), ALP (U/L)  38.5 456.5 (92–1.238)  40.0 305 (100–1.002)
Aspartate aminotransferase, AST (U/L)  0.7 22.5 (13–44)  0.3 22.0 (13–47)
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omalizumab clinical trials programme. In addition, there
have been no spontaneous post-marketing reports of
helminth infection in the United States since launch in
more than 39000 patients. The population targeted for
this study was selected to allow a meaningful number of
infection events to be evaluated in an experimental
context. This requirement led to severe recruitment pro-
blems as (1) heavily infected and exposed individuals (i.e.
at highest risk of infection) had total IgE levels that were
considerably in excess of the upper IgE limit for inclusion
(41300IU/mL); and (2) allergic individuals (with a dis-
ease proﬁle likely to respond to omalizumab therapy)
have a low risk of infection with geohelminth parasites.
Recent studies have shown strong inverse relationships
between intestinal helminth infections and atopy [18, 19]
or asthma [19, 21], which may indicate that allergic
individuals are more resistant to helminth infections. It
would appear unlikely, therefore, that a larger rando-
mized-controlled trial could be performed in the future,
and the data from the present study are therefore impor-
tant for the information they provide on safety.
We also assessed safety using several parasitologic
parameters designed to detect the rapid acquisition of
heavy helminth burdens (time to treatment with anthel-
mintics), a tendency towards higher helminth burdens
(maximal infection intensities and requirement for addi-
tional anthelmintic treatments) and response to anthel-
mintic treatment (immune-dependent response). These
parameters were similar in both treatment groups. Overall,
the safety data suggest that omalizumab treatment is not
associated with clinically relevant AEs that might be
caused by helminth infection, and they provide evidence
that omalizumab can be safely administered to allergic
patients who travel to or work temporarily in areas that
are endemic for intestinal helminths. The data also show
that anthelmintic drugs can be administered to patients
who are receiving omalizumab and who are infected with
helminth parasites without a loss of therapeutic efﬁcacy.
This may not be surprising because the effects of anthel-
mintic drugs on adult worms in the intestine are not
thought to depend on host immunity.
The study was conducted in allergic subjects considered
to be at risk of intestinal helminth infection. The study
population was, in many ways, somewhat atypical of
individuals who live in highly endemic areas for geohel-
minth infection because of signiﬁcant allergic disease and
relatively low IgE levels (41300IU/mL). Populations
living in areas that are highly endemic for geohelminth
parasites tend to have very high levels of polyclonal IgE
[21], a low risk of allergic disease, with severe allergic
disease being particularly rare [22]. The study population
in the present study represents a population of individuals
with allergic disease at risk of geohelminth infection
through living in poor urban areas of Brazil.
The study provided a unique opportunity to examine the
protective role of IgE against intestinal helminth parasites.
There is a general belief that IgE is an important mediator
of host immunity against helminth parasites [23–25],
although much of the evidence is conﬂicting and derives
from experimental animal models [26, 27].Theﬁnding of a
possible increased risk of intestinal helminth infection in
individuals receiving omalizumab treatment is consistent
with a protective role for this Ig. However, the estimated
risks were relatively modest, lending support to observa-
tions from animal models that suggest a non-critical role
for IgE in protective immunity [4]. There were too few
infections with S. stercoralis (omalizumab 0 vs. placebo 2
infections) to allow an evaluation of safety in this study.
S. stercoralis is unusual in that it is capable of replicating
within the human host, and occasionally may cause a
severe and potentially fatal condition, Strongyloides hy-
perinfection, which is associated with speciﬁc acquired
immune deﬁciency disorders. Some concern for a potential
increased risk of Strongyloides hyperinfection in patients
takingomalizumabisjustiﬁed,althoughthe riskislikelyto
be no greater than with more broadly immunosuppressive
treatments such as oral corticosteroids that have been
associated with hyperinfection [28]. As when considering
treatment with oral corticosteroids, speciﬁc groups of
allergic individuals being considered for treatment with
omalizumab and who are at a particularly high risk of
Strongyloides infection should have a parasitologic assess-
ment before the start of treatment to exclude active
strongyloidiasis. Such individuals might includeinstitutio-
nalized psychiatric patients, the indigent (i.e. impoverished
individuals lacking necessities such as food and shelter)
and refugees or migrants from endemic areas. Individuals
at a high risk of the hyperinfection syndrome and who
have active Strongyloides infections should probably be
excluded from omalizumab treatment, as would occur in
individuals with haematologic malignancies and human T
lymphotrophic virus type-1 (HTLV-1) co-infection [29].
In conclusion, this randomized-controlled trial pro-
vides evidence that omalizumab can be safely used to
treat AA and PAR in patients considered to be at risk of
common intestinal helminth infections. Because we were
unable to obtain sufﬁcient data on strongyloidiasis, we
cannot exclude a safety risk for this infection, although
the theoretical risk could be minimized by adequate
screening of at-risk subjects, before the start of therapy.
There was some evidence for a slightly increased inci-
dence of intestinal helminth parasite infection among
subjects receiving omalizumab, but this possible excess
infection risk did not appear to be clinically signiﬁcant.
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206 A. A. Cruz et alAppendix A1
Dosing tables for omalizumab administered by subcuta-
neous injection every 4 weeks (A) or every 2 weeks (B).
Omalizumab doses are given in milligrams per dose. These
dosing tables differ from the dosing tables provided in the
package inserts of the marketed product.
Appendix A1. Dosing tables for omalizumab administered by subcutaneous injection every 4 weeks (A) or every 2 weeks (B)
Baseline
IgE (IU/mL)
Bodyweight (kg)
>20–30 >30–40 >40–50 >50–60 >60–70 >70–80 >80–90 >90–125 >125–150
A
X30–100 150 150 150 150 150 150 150 300 300
>100–200 150 150 300 300 300 300 300
>200–300 150 300 300 300
>300–400 300 300
>400–500 300 Administration every 2 weeks see Part B
>500–600 300
B
X30–100 Administration every 4 weeks see Part A
>100–200 225 300
>200–300 225 225 225 300 375
>300–400 225 225 225 300 300
>400–500 225 225 300 300 375 375
>500–600 225 300 300 375
>600–700 225 225 300 375
>700–800 225 300 375
>800–900 225 300 375
>900–1000 300 375 DO NOT DOSE
>1000–1100 300 375
>1100–1200 300
>1200–1300 375
Omalizumab doses are given in mg/dose.
These dosing tables differ from the dosing tables provided in the package inserts of the marketed product.
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